| scholarly article | Q13442814 |
| P50 | author | Matthew Zabel | Q57425681 |
| P2093 | author name string | Claudius Mueller | |
| Matthew Schrag | |||
| Wolff M Kirsch | |||
| Weidong Zhou | |||
| Andrew Crofton | |||
| April Dickson | |||
| Floyd Petersen | |||
| P2860 | cites work | Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. | Q53237539 |
| Serum concentration of alpha 1-antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type. | Q53301471 | ||
| Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. | Q53376534 | ||
| Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. | Q53388392 | ||
| Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response | Q71686650 | ||
| Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients | Q72185731 | ||
| Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland | Q73540046 | ||
| Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease | Q73881108 | ||
| Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease | Q82774518 | ||
| Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke | Q24317703 | ||
| Biological markers of amyloid beta-related mechanisms in Alzheimer's disease | Q24622136 | ||
| Mild cognitive impairment: clinical characterization and outcome | Q28140626 | ||
| Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
| Mining biomarkers in human sera using proteomic tools | Q33196952 | ||
| Multimodal techniques for diagnosis and prognosis of Alzheimer's disease | Q33607535 | ||
| Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease | Q34043074 | ||
| Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations | Q34445192 | ||
| Proteome-based plasma biomarkers for Alzheimer's disease | Q34577503 | ||
| 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function | Q34654085 | ||
| Up-regulated production and activation of the complement system in Alzheimer's disease brain | Q35786312 | ||
| Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation | Q35985986 | ||
| The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease | Q36660120 | ||
| Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease? | Q36947889 | ||
| Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia | Q37457153 | ||
| Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. | Q37493113 | ||
| Complement in neuroprotection and neurodegeneration | Q37684123 | ||
| Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease | Q41049437 | ||
| Acute-phase proteins in Alzheimer's disease. | Q41252635 | ||
| Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients | Q41895354 | ||
| Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease | Q42044152 | ||
| Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease | Q43722364 | ||
| Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia | Q44420268 | ||
| Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease | Q44784618 | ||
| Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease | Q46155330 | ||
| Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. | Q47594886 | ||
| Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease | Q48134664 | ||
| Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. | Q48223542 | ||
| Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease | Q48516355 | ||
| Neurons express proteins of the classical complement pathway in Alzheimer disease | Q48592170 | ||
| alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. | Q48677175 | ||
| Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target. | Q48838648 | ||
| Platelet C4d is associated with acute ischemic stroke and stroke severity. | Q48876520 | ||
| Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. | Q51762261 | ||
| Serum biomarkers for Alzheimer's disease: proteomic discovery. | Q51911080 | ||
| Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. | Q51951302 | ||
| Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. | Q53201380 | ||
| Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. | Q53210231 | ||
| Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. | Q53226489 | ||
| Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? | Q53233114 | ||
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| P304 | page(s) | 311-321 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study | |
| P478 | volume | 30 |
| Q51760901 | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. |
| Q47105056 | Comparative profiling of cortical gene expression in Alzheimer's disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation |
| Q47709505 | Complement in the pathogenesis of Alzheimer's disease. |
| Q98665006 | EEG microstates as biomarker for psychosis in ultra-high-risk patients |
| Q90045053 | Molecular form and concentration of serum α2-macroglobulin in diabetes |
| Q38881022 | Neuropsychological Effects of Cerebral Amyloid Angiopathy |
| Q58779295 | Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias |
| Q60949612 | Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis |
Search more.